Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Onconova Therapeutics (ONTX) Stock Price

News coverage about Onconova Therapeutics (NASDAQ:ONTX) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Onconova Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.9142129534968 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Several equities analysts have recently commented on the stock. Maxim Group restated a “buy” rating and set a $6.00 price target on shares of Onconova Therapeutics in a report on Thursday, November 2nd. HC Wainwright restated a “buy” rating on shares of Onconova Therapeutics in a report on Thursday, November 9th. Finally, Zacks Investment Research upgraded shares of Onconova Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. Onconova Therapeutics currently has an average rating of “Hold” and an average price target of $7.33.

Onconova Therapeutics (ONTX) traded up $0.01 during mid-day trading on Monday, hitting $1.07. 75,600 shares of the company traded hands, compared to its average volume of 447,261. Onconova Therapeutics has a 1-year low of $0.95 and a 1-year high of $3.88. The firm has a market cap of $20.78, a price-to-earnings ratio of -0.39 and a beta of 0.08.

In other Onconova Therapeutics news, major shareholder 683 Capital Management, Llc acquired 200,000 shares of Onconova Therapeutics stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average price of $1.04 per share, with a total value of $208,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 29.10% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Onconova Therapeutics (ONTX) Stock Price” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Insider Buying and Selling by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply